NHS: Stay Away From This 17% Yielder As Rates Rise (Rating Downgrade)
Neuberger High Yield Strategies Fund is downgraded to a sell due to persistent NAV erosion and unsustainable distributions. NHS trades at a 6.6% discount to NAV and offers a 17.4% yield, but earnings consistently fail to cover payouts, risking further capital deterioration. Leverage at 26.7% and 98% below-investment-grade exposure amplifies risks in a rising rate and higher default environment.
NHS: Too Expensive Given The Unsustainable Distribution And Bond Market Troubles
The Neuberger High Yield Strategies Fund offers a headline 16.66% yield, the highest among closed-end junk bond peers. NHS is not covering its distribution with investment income, as net asset value has declined 10.22% over two years, signaling unsustainable payouts. The fund's portfolio is concentrated in BB and B-rated high-yield bonds, balancing risk and income but sacrificing some yield versus lower-rated debt.
Novo Nordisk stock surges 4%: can NHS boost offset pricing pressure?
Novo Nordisk stock surged on Wednesday after a major policy win, which is seen as a turning point for the drugmaker. England's cost-effectiveness watchdog has backed broader use of Wegovy to cut the risk of heart attacks and strokes in overweight or obese adults.
Eli Lilly seeks higher NHS drug prices, rebate overhaul to restart UK investment, FT reports
Eli Lilly wants the UK to regularly raise NHS drug prices and phase out a multi-billion-pound rebate scheme if it is to resume investment, its international businesses president Patrik Jonsson told the Financial Times.
NHS: Dividend Isn't Supported By Earnings
Neuberger High Yield Strategies remains rated Hold due to persistent NAV declines and inadequate dividend coverage. NHS's 14.9% yield is attractive, but net investment income consistently falls short of distributions, increasing reliance on volatile realized gains. Leverage at 30% of assets amplifies both yield and risk, especially amid high interest rates and a predominantly below-investment-grade portfolio.
Ondine Biomedical's Steriwave shortlisted for NHS partnership award
Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) told investors it has been shortlisted for the 2026 HSJ Partnership Awards. The nomination follows the use of its Steriwave nasal decolonisation technology by Mid Yorkshire Teaching NHS Trust to reduce post-surgical infections.
Is Trump targeting the NHS in trade negotiations? This reports says it is
Britain could face higher drug costs as part of a deal to stave off future tariffs from Donald Trump, according to a report in the Daily Telegraph. Documents released after a recent trade agreement show the NHS is expected to review its approach to drug pricing in response to US demands.
